• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Managing patients with ibrutinib-resistant CLL: don't stop ibrutinib until you are ready with the next therapy.

作者信息

Tang Pek Sang Chloe, Tam Constantine

机构信息

Department of Haematology, St Vincent's Hospital, Melbourne, Australia.

出版信息

Leuk Lymphoma. 2019 Nov;60(11):2602-2603. doi: 10.1080/10428194.2019.1616189. Epub 2019 May 17.

DOI:10.1080/10428194.2019.1616189
PMID:31099285
Abstract
摘要

相似文献

1
Managing patients with ibrutinib-resistant CLL: don't stop ibrutinib until you are ready with the next therapy.治疗对依鲁替尼耐药的慢性淋巴细胞白血病患者：在下一种治疗准备好之前，不要停用依鲁替尼。
Leuk Lymphoma. 2019 Nov;60(11):2602-2603. doi: 10.1080/10428194.2019.1616189. Epub 2019 May 17.
2
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.停用依鲁替尼的慢性淋巴细胞白血病患者的长期预后。
Cancer. 2017 Jun 15;123(12):2268-2273. doi: 10.1002/cncr.30596. Epub 2017 Feb 7.
3
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.伊布替尼治疗中断的病因及慢性淋巴细胞白血病患者的结局。
JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218.
4
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.NOTCH1 活性降低与慢性淋巴细胞白血病对依鲁替尼的反应相关。
Clin Cancer Res. 2019 Dec 15;25(24):7540-7553. doi: 10.1158/1078-0432.CCR-19-1009. Epub 2019 Oct 2.
5
Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.伊布替尼治疗后复发风险高的慢性淋巴细胞白血病患者的管理
Leuk Lymphoma. 2018 Oct;59(10):2287-2296. doi: 10.1080/10428194.2017.1397665. Epub 2017 Nov 8.
6
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.420毫克剂量的单药伊布替尼延长治疗可使慢性淋巴细胞白血病/小淋巴细胞淋巴瘤产生持久反应。
Clin Cancer Res. 2017 Mar 1;23(5):1149-1155. doi: 10.1158/1078-0432.CCR-16-1431. Epub 2017 Jan 10.
7
Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison.苯达莫司汀与伊布替尼治疗初治慢性淋巴细胞白血病患者的疗效与安全性：间接比较
Clin Lymphoma Myeloma Leuk. 2017 May;17(5):268-273. doi: 10.1016/j.clml.2017.02.026. Epub 2017 Mar 7.
8
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.依鲁替尼与医生选择的治疗方案以及idelalisib联合奥法木单抗用于既往治疗的慢性淋巴细胞白血病患者的间接治疗比较
Clin Ther. 2017 Jan;39(1):178-189.e5. doi: 10.1016/j.clinthera.2016.12.001. Epub 2017 Jan 3.
9
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome.依鲁替尼治疗复发性慢性淋巴细胞白血病患者并使 Richter 综合征持续缓解。
Tumori. 2017 Nov 15;103(Suppl. 1):e37-e40. doi: 10.5301/tj.5000667.
10
Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.伊布替尼用于治疗慢性淋巴细胞白血病和套细胞淋巴瘤。
Drugs Today (Barc). 2014 Apr;50(4):291-300. doi: 10.1358/dot.2014.50.4.2133570.

引用本文的文献

1
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病患者伊布替尼治疗临时中断期间的疾病 flares。
Oncologist. 2020 Nov;25(11):974-980. doi: 10.1634/theoncologist.2020-0388. Epub 2020 Sep 20.